Literature DB >> 27922756

Translation and Psychometric Evaluation of a Korean Version of the Amyotrophic Lateral Sclerosis-Specific Quality of Life - Revised.

Juyeon Oh1,2, Gwi-Ryung Son Hong1, Seung Hyun Kim2,3, Jung A Kim1.   

Abstract

OBJECTIVE: The objective was to translate the Amyotrophic Lateral Sclerosis-Specific Quality of Life - Revised instrument (ALSSQOL-R) into Korean and to examine the psychometric properties of the Korean amyotrophic lateral sclerosis (ALS) population.
METHODS: The translation involved forward and backward translation. The psychometric properties of the Korean version of the ALSSQOL-R (K-ALSSQOL-R) were tested by patients in an ALS multidisciplinary clinic in Korea (n = 120). The internal consistency, test-retest reliability, content validity, criterion-related validity, and construct validity were evaluated.
RESULTS: With regard to the reliability estimate, the internal consistency (Cronbach's alpha = 0.92) and the test-retest reliability (ICC = 0.89) were good. With regard to the validity estimate, the K-ALSSQOL-R demonstrated concurrent validity with the McGill Quality of Life Single-Item Scale (r = 0.62) and the first question of the World Health Organisation QOL Instrument-Brief (WHOQOL-BREF) (r = 0.64). The convergent validity and discriminant validity were acceptable. The confirmatory factor analysis supported a six-factor model.
CONCLUSION: The K-ALSSOQL-R can be used as a reliable and valid measure of QOL among Korean ALS patients.

Entities:  

Keywords:  Amyotrophic Lateral Sclerosis; psychometrics; quality of life; reliability and validity; translation

Mesh:

Year:  2016        PMID: 27922756     DOI: 10.1080/21678421.2016.1249885

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  1 in total

1.  A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis.

Authors:  Emily Beswick; Deborah Forbes; Zack Hassan; Charis Wong; Judith Newton; Alan Carson; Sharon Abrahams; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2021-06-13       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.